Compare SOLAI Limited (SLAI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs Vertex Pharmaceuticals Incorporated — how do they compare? SOLAI Limited trades at $3.72 (market cap $880.09M), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 144.9× SOLAI Limited's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SOLAI Limited for 40 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SLAI | VRTX | |
|---|---|---|
Market Cap | $880.09M | $127.55B |
Volume | 122,720 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $21.63 | $557.96 |
52-Week Low | $2.74 | $407.37 |
Typical Hold Time | 40 Days | 120 Days |
Enterprise Value | $879.73M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement. The stock shows a bullish technical signal despite concerning fundamentals, including negative profit margins (-134.76% net income margin) and declining revenue from $57M in 2022 to $23M in 2025. The company received a delisting notice from NYSE in July 2026, creating significant uncertainty. Cash flow remains negative at -$1.47M, though the P/B ratio of 0.35 suggests potential undervaluation based on book value.
Outlook remains highly speculative given delisting proceedings and persistent losses. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment. Investment opportunity exists only for risk-tolerant investors betting on turnaround potential, while major risks include delisting execution, continued cash burn, and competitive pressures in the AI infrastructure space.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
